Indian companies maintained their dominance in the IPM with a share of 79 per cent and grew combined at a strong 11 per cent growth rate
The Indian Pharmaceutical Market (IPM) clocked Rs 120788 crores and grew at 6.3 per cent as of MAT February 2018 and was valued at Rs 9992 crores for the month of February. The retail sector was valued at Rs 102188 crores and showed a growth of 7.0 per cent. The growth for IPM was 10 per cent.
Top 10 companies showed a double digit growth of 11 per cent over SPLY and clocked a combined revenue of Rs 4319 crores with their share slight decreasing and coming down to 43 per cent in the IPM. Rank 4-7 set of top 10 companies grew in double digits with Mankind (21 per cent), Alkem (16 per cent), Macleods (14 per cent) and Lupin (11 per cent) being amongst companies with strong growths. Companies in 11-20 bracket grew even better at 13 per cent combined where Aristo (19 per cent) and Glenmark (13 per cent) were among the fastest growing companies.
Top 10 brands in the IPM were valued at Rs 322 crores combined and showed a growth of 9 per cent which was slightly lesser than the IPM. 7 of the top 10 brands showed double digit growth with Clavam (26 per cent) and Thyronorm (23 per cent) leading the way for the month of February 2018. Only Novomix (-21 per cent) showed de-growth among top 10 brands. Brands ranked 11-20 grew strongly at 18 per cent combined growth where Panderm+ (56 per cent) and Monocef (36 per cent) were amongst the fastest growing. These brands were valued at Rs 231 crore for the month.
Indian companies maintained their dominance in the IPM with a share of 79 per cent and grew combined at a strong 11 per cent growth rate. MNCs on the other hand continued to grow at single digits with a growth of 7 per cent and share of 21 per cent in the IPM. Five of the top 10 Indian companies registered a strong double digit growths. No. 1 Indian company Sun grew at 6 per cent while Mankind (21 per cent) was the fastest growing Indian company followed by Alkem (16 per cent) and Macleods (14 per cent). The top MNC Abbott showed a strong growth of 9 per cent over SPLY. None of the top 10 MNCs showed double digit growth.
Acute therapy with a growth of 11 per cent for the month of February ’18 continued its trend of last few months of growing better than chronic therapy which grew at 8 per cent. Acute therapy also increased its share by 1 per cent to 65 per cent in IPM as compared to Chronic coming down to 35 per cent share. Anti-infectives (16 per cent), Derma (10 per cent) and Respiratory (23 per cent) continued to be the growth driver for Acute Therapy. Comparatively subdued growths were registered by the top therapies cardiac (7 per cent) and anti-diabetes (8 per cent) in chronic.
Anti-infective therapy was valued at Rs 1253 crores with a strong growth of 16 per cent. All of the Top 10 molecules grew in double digits with Amikacin (31 per cent), Cefpodoxime Solids (29 per cent) and Ceftriaxone Injectables (28 per cent) showing the fastest growths. Top molecule Amoxycillin and Clavulanic Acid Solids also showed a strong 21 per cent growth. Nine of the top 10 brands showed a strong double digit growth with the No. 1 brand Augmentin growing at 14 per cent over SPLY. Other Top 10 brands which showed a strong growth are Monocef (36 per cent), Moxikind-CV (31 per cent) Azithral (38 per cent) and Mikacin (51 per cent).
Cardiac therapy continued to be the second largest therapy in IPM clocking a revenue of Rs 1179 crores and a growth of 7 per cent on SPLY. While the top molecule Rosuvastatin (6 per cent) showed a decent growth, the No.2 molecule Atorvastatin (0 per cent) displayed no growth over SPLY. On the other hand molecules like Amlodipine + Telmisartan (11 per cent), Enoxaparin (13 per cent) and Cilnidipine (18 per cent) were those top 10 molecules which registered strong growths. Combinations (10 per cent) continued to show a better growth as compared to Plain molecules (6 per cent). While 7 of the Top 10 brands showed strong double digit growths with Cilacar (24 per cent) and Dytor (22 per cent) growing more than 20 per cent, brands like Nikoran (-14 per cent) continued to de-grow. Top brand Rosuvas grew at 5 per cent.
Gastro intestinal therapy maintained its No. 3 rank in IPM with a value of Rs 1032 crores for the month and a growth of 8 per cent which was slightly slower than the IPM. Only three of the top 10 molecules in the therapy registered a double digit growth with Oral Electrolytes (21 per cent) topping the chart in terms of growth. Ranitidine Oral Solids (-1 per cent) was the only molecule among top 10 to register degrowth. The top 2 molecules Pantoprazole + Domperidome (65 crores) and Rabeprazole + Domepridome (56 crores) continued to growth at a slower pace of 3 per cent and 2 per cent respectively. Among top 25 molecules Bacillus Clausii’s growths remained strong at 35 per cent whereas Esomeprazole + Domperidome also grew strog at 22 per cent. All the top 3 brands showed a strong double digit growth with No. 1 brand Spasmo-Proxyvon+ growing at 11 per cent while the newly crowned No.2 brand Electral showed a strong 22 per cent growth over SPLY. On the other hand PAN-D (-5 per cent) showed a negative growth for the month of February 2018.
Anti-diabetics for the first time in many months lost its fourth positon to respiratory and moved one position down to become the fifth largest therapy in the IPM for the month of February 2018 clocking a revenue of Rs 913 crores for the month with a growth of 8 per cent. While all the top 10 molecules grew positively, the No.1 molecule Glimepiride + Metformin showed a subdued growth of 3 per cent over SPLY. SGLT2 inhibitors however continued their progress clocking a growth of 49 per cent over SPLY. In DPP4 inhibitors molecules like Metformin + Sitagliptin (14 per cent) and Metformin + Teneligliptin (59 per cent) continued to grow strongly whereas Metformin + Vildagliptin (3 per cent) and Vildagliptin (-5 per cent) could not show a strong performance. Only 4 of the top 10 brands grew in double digits where Lantus (18 per cent), Janumet (13 per cent), Jalra (18 per cent) and Istamet (16 per cent) grew strongly. However 2 of the top 10 brands Novomix (-21 per cent) and Galvus (-3 per cent) also showed de-growth.
Dermatology registered Rs 728 crores of revenue with a growth of 10 per cent for the month of February 2018. This was a much slower growth registered by the therapy as compared to previous few months. Six of the top 10 molecules grew in double digits while the top category Emollients Protectives growing at 13 per cent for the month. The Antifungal category continued its progress with both top molecules Itraconazole (42 per cent) and Luliconazole (97 per cent) growing strongly. Also Clobetasole + Ofloxacin + Ornidazole + Terbinafine with a growth of 49 per cent was another molecule which showed strong performance. Panderm+ continued to retain its top position and grew at 56 per cent with the No.2 brand Betnovate-N also showing a strong growth of 17 per cent. Betadine (-2 per cent) and Skinlite (-3 per cent) were the only 2 brands among top 10 to show de-growth. Candiforce (37 per cent), T-Bact (17 per cent) and Lulifin (26 per cent) were some other brands among top 10 to perform strongly.